# Going for three: what is the role for triplex testing for HSV-1, HSV-2, and VZV?

**Authors:** David R. Peaper

PMC · DOI: 10.1128/asmcr.00152-25 · ASM Case Reports · 2025-11-04

## TL;DR

The paper discusses the importance of triplex testing for HSV-1, HSV-2, and VZV to improve accurate diagnosis and patient management.

## Contribution

The paper highlights the limitations of current diagnostic methods and advocates for triplex NAATs to enhance viral identification and infection control.

## Key findings

- Provider-ordered testing often misses the causative virus in mucocutaneous lesions.
- Triplex NAATs could improve patient management and infection prevention practices.
- Clinical diagnosis alone may be insufficient to differentiate HSV-1, HSV-2, and VZV.

## Abstract

Herpes simplex virus-1 (HSV-1), HSV-2, and varicella zoster virus (VZV) are common causes of mucocutaneous lesions. Diagnostic methods have shifted from culture or direct fluorescent antibody testing to nucleic acid amplification tests (NAATs), but testing is (i) not often undertaken or (ii) often specific for either HSV-1/2 or VZV based upon classic clinical findings associated with typical disease. A recent study by B. W. Buchan and P. Pancholi published in ASM Case Reports (2:e00112-25, 2025, https://doi.org/10.1128/asmcr.00112-25) highlights the limitations of this approach, revealing a substantial number of cases where provider-ordered testing missed the causative virus. Accurate viral identification is critical in these cases, as missed or misdiagnosis impacts patient management. Treatment regimens, including antiviral dosage and duration, vary among clinical presentations of HSV-1, HSV-2, and VZV. More importantly, infection control protocols differ among these pathogens. Many cases of VZV require airborne and contact isolation in healthcare settings to prevent nosocomial transmission, a precaution not necessary for most HSV-1/2 infections. In some cases, clinical diagnosis may be insufficient for differentiation among HSV-1, HSV-2, and VZV. More studies are needed to help identify use cases where triplex testing is most appropriate, but broader availability and implementation of triplex NAATs have the potential to promote better patient management and infection prevention practices.

## Full-text entities

- **Diseases:** mucocutaneous lesions (MESH:D007897), HSV-1/2 infections (MESH:D006561), infection (MESH:D007239)
- **Species:** Human alphaherpesvirus 1 (Herpes simplex virus type 1, no rank) [taxon 10298], Homo sapiens (human, species) [taxon 9606], Human alphaherpesvirus 3 (Varicella-zoster virus, no rank) [taxon 10335], Human alphaherpesvirus 2 (no rank) [taxon 10310]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12772232/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12772232/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12772232/full.md

---
Source: https://tomesphere.com/paper/PMC12772232